What is Affinity Biosensors?
Affinity Biosensors is a specialized medical technology firm focused on the development of rapid antimicrobial susceptibility testing (AST) solutions. At the core of its product portfolio is the LifeScale system, an advanced platform that utilizes population profiling technology to deliver precise diagnostic results in a fraction of the time required by traditional methods. By providing actionable data in just four hours, the LifeScale system addresses a critical gap in clinical workflows, particularly within intensive care units where time-sensitive decisions are paramount.
The company serves a diverse range of healthcare institutions and diagnostic laboratories, positioning itself as a vital partner in the global fight against antimicrobial resistance. Through seamless integration into existing laboratory infrastructures, Affinity Biosensors enhances operational efficiency while simultaneously improving patient outcomes, establishing itself as a high-authority player in the diagnostic technology sector.
How much funding has Affinity Biosensors raised?
Affinity Biosensors has raised a total of $15.2M across 6 funding rounds:
Private Equity
$1.3M
Series A
$7.1M
Private Equity
$4.8M
Debt
$150K
Debt
$347K
Private Equity
$1.6M
Private Equity (2013): $1.3M, investors not publicly disclosed
Series A (2016): $7.1M, investors not publicly disclosed
Private Equity (2017): $4.8M, investors not publicly disclosed
Debt (2020): $150K featuring PPP
Debt (2021): $347K backed by PPP
Private Equity (2026): $1.6M, investors not publicly disclosed
Key Investors in Affinity Biosensors
Undisclosed Investor
An institutional partner providing capital to support the long-term growth and operational scaling of the company.
PPP
Public-Private Partnership
Undisclosed Investor
A private equity participant specializing in the advancement of high-growth medical technology and diagnostic firms.
What's next for Affinity Biosensors?
With the successful closure of this latest financing round, Affinity Biosensors is poised to enter a new phase of commercial expansion and technological refinement. The strategic allocation of these funds will likely prioritize the scaling of manufacturing capabilities to meet rising demand for the LifeScale system, alongside continued investment in research and development to broaden the platform's diagnostic capabilities.
Furthermore, the company is expected to leverage this capital to strengthen its market presence, potentially pursuing strategic partnerships with major healthcare providers and diagnostic networks. As the global healthcare industry continues to prioritize rapid, accurate testing to combat the rise of resistant pathogens, Affinity Biosensors remains at the forefront of innovation, well-equipped to navigate the complexities of the clinical diagnostics market and deliver long-term value to its stakeholders.
